Table 4.
Association Between Preoperative Clinical Factors and the Extent of Surgical Resection in Patients With MMR-Deficient Rectal Cancer
| Factor | All Patients Undergoing Resection (N = 59) | Segmental Procedures (n = 41; 69.5%) | Extended Procedure (n = 11; 18.6%) | Local Excision (n = 7; 11.9%) | P |
|---|---|---|---|---|---|
| Age at rectal cancer diagnosis (median), years | 41 | 40 | 44 | 56 | .047 |
| Sex, female | 28 (47.5) | 20 (48.8) | 3 (27.3) | 5 (71.4) | .179 |
| Rectal cancer presentation | |||||
| Index and only cancer | 55 (93.2) | 40 (97.5) | 10 (90.9) | 5 (71.4) | .037 |
| Index, with synchronous colonic HGD or adenocarcinoma | 12 (20.3) | 4 (9.7) | 7 (63.6) | 1 (17.3) | < .001 |
| Metachronous to a prior colon cancer | 3 (5.1) | 3 (7.3) | 0 (0) | 0 (0) | .500 |
| Rectal cancer distance from anal verge (median), cm | 7 | 7 | 12 | 2 | .004 |
| Clinical stage of rectal cancer | .002 | ||||
| cT1-2N0 | 15 (25.4) | 5 (12.2) | 4 (36.4) | 6 (85.7) | |
| cT3-4N0 | 13 (22.0) | 10 (24.4) | 3 (27.3) | 0 (0) | |
| cTanyN-positive | 26 (44.1) | 22 (53.7) | 3 (27.3) | 1 (14.3) | |
| cTanyNanyM-positive | 4 (6.8) | 4 (9.7) | 0 (0) | 0 (0) | |
| Neoadjuvant chemoradiation | 33 (55.9) | 28 (68.3) | 4 (36.4) | 1 (14.3) | .010 |
| Multivisceral resection | 17 (28.8) | 13 (31.7) | 4 (36.4) | 0 (0) | .191 |
| Pathogenic germline MMR mutation identified | 39 (66.1) | 27 (65.9) | 8 (72.7) | 4 (57.1) | .792 |
NOTE. Data presented as No. (%).
Abbreviations: HGD, high-grade dysplasia; MMR, mismatch repair.